Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Diagnostic accuracy of CERAD total score in a Colombian cohort with mild cognitive impairment and Alzheimer's disease affected by E280A mutation on presenilin-1 gene.

International psychogeriatrics - 1 Mar 2016

Aguirre-Acevedo Daniel Camilo, Jaimes-Barragán Fabian, Henao Eliana, Tirado Victoria, Muñoz Claudia, Reiman Eric M, Tariot Pierre N, Langbaum Jessica B, Lopera Francisco

Abstract excerpt

BACKGROUND: This study aimed to determine Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Neuropsychological Assessment Battery total score diagnostic accuracy in the diagnosis of mild cognitive impairment (MCI) and dementia in familial Alzheimer's disease (FAD) with E280A mutation on presenilin-1 gene (PSEN1). METHODS: A cross-sectional study was conducted in a cohort of PSEN1 E280A carriers...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Cognitive Dysfunction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colombia

Share to Neuropsychological Tests

Share to Presenilin-1

Share to Recognition, Psychology

Share to Sensitivity and Specificity

Share to Severity of Illness Index

Source

Identifiers

PMID: 26478578
DOI: 10.1017/S1041610215001660

Genes

PSEN1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Diagnostic accuracy of CERAD total score in a Colombian cohort with mild cognitive impairment and Alzheimer's disease affected by E280A mutation on presenilin-1 gene.PMID 26478578Read ↗

Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study.Semantic proximity Read ↗

Cognitive Outcomes in Autosomal-Dominant Alzheimer's Disease: A Comprehensive Review from a Colombian Kindred with the Presenilin-1 E280A Mutation.Semantic proximity Read ↗

Phenotypic profile of early-onset familial Alzheimer's disease caused by presenilin-1 E280A mutation.Semantic proximity Read ↗

Sex Differences in Cognitive Abilities Among Children With the Autosomal Dominant Alzheimer Disease Presenilin 1 E280A Variant From a Colombian Cohort.Semantic proximity Read ↗

Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation.Semantic proximity Read ↗

Preserved cognitive-functional phenotype in centenarians and its association with modifiable risk factors for dementia: Results from the Colombian centenarians project.Semantic proximity Read ↗

Neuropsychological study of familial Alzheimer's disease caused by mutation E280A in the presenilin 1 gene.Semantic proximity Read ↗

Associations of plasma biomarkers with age in the presenilin-1 E280A autosomal dominant Alzheimer's disease kindred.Semantic proximity Read ↗

The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.Semantic proximity Read ↗

Absolute 10-year risk of dementia by age, sex and APOE genotype: a population-based cohort study.Semantic proximity Read ↗

Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia Trial.Semantic proximity Read ↗

Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.